Table 4.
Relative Response Rate of Physician Global Assessment Clearance,a and Response Rate Differences by Current Monotherapy and Combination Therapy
| Current Treatment |
Unadjusted RR (95% CI) |
Adjusted RR (95% CI)b |
Risk Difference (95% CI)c |
NNTd |
|---|---|---|---|---|
| Methotrexate sodium (n=168) | 1 [Reference] | 1 [Reference] | ||
| Acitretin (n=37) | 1.58 (0.93–2.66) | 2.01 (1.18–3.41) | 0.22 (0.04–0.54) | 4.4 |
| Cyclosporine (n=19) | 1.65 (0.86–3.18) | 1.44 (0.75–2.74) | 0.10 (−0.05–0.39) | NA |
| Infliximab (n=42) | 2.08 (1.35–3.21) | 1.93 (1.26–2.98) | 0.21 (0.06–0.44) | 4.8 |
| Adalimumab + Methotrexate (n=49) | 2.66 (1.84–3.83) | 3.04 (2.12–4.36) | 0.45 (0.25–0.75) | 2.2 |
| Etanercept + Methotrexate (n=22) | 2.24 (1.35–3.72) | 2.22 (1.25–3.94) | 0.27 (0.05–0.66) | 3.7 |
| Infliximab + Methotrexate (n=34) | 1.98 (1.23–3.18) | 1.72 (1.10–2.70) | 0.16 (0.02–0.38) | 6.2 |
Abbreviations: CI, confidence interval; NA, not applicable; NNT, number needed to treat; RR, relative risk.
a
Physician Global Assessment Clearance defined as clear or almost clear disease (PGA ≤ 1).
b
Adjusted for age, sex, marital status, practice setting of dermatologist, body mass index, psoriasis response to natural light,prescription topical medication frequency.
c
Difference between adjusted and baseline risk.
d
Number of patients needed to treat with the particular treatment to gain 1 additional patient with PGA clearance relative to theresponse achieved with methotrexate.